Effects of vasoactive intestinal peptide (VIP) and peptide histidine methionine (PHM) on basal and gorticotropin-releasing hormone (CRH)-stimulated ACTH/cortisol secretion in Cushing's disease

B. Ambrosi, P. Colombo, T. Re, E. Passini, D. Bochicchio

Research output: Contribution to journal › Article › peer-review

Abstract

The possible role of Vasoactive Intestinal Peptide (VLP) and Peptide Histidine Methionine (PHM) as neuromodulators of anterior pituitary function in humans has been suggested. In this work the effects of VIP and PHM on basal and CRH-stimulated ACTH/F secretion were studied in 7 patients with Cushing's disease. An ACTH/F response was found in 3 cases during PHM infusion and in 2 of 6 patients during VIP infusion. When compared to CRH alone, a blunted ACTH response to CRH during PHM occurred in 5 tested patients and during VIP in 3 cases. In conclusion, VIP and PHM are able to rise ACTH/F secretion in some patients with Cushing's disease, but are unable to potentiate the response to CRH, which rather may be reduced.

Original languageEnglish
Pages (from-to)313-318
Number of pages6
JournalNeuroendocrinology Letters
Volume17
Issue number4
Publication statusPublished - 1995

ASJC Scopus subject areas

  • Endocrinology
  • Neuroscience(all)

Access to Document

Fingerprint Dive into the research topics of 'Effects of vasoactive intestinal peptide (VIP) and peptide histidine methionine (PHM) on basal and gorticotropin-releasing hormone (CRH)-stimulated ACTH/cortisol secretion in Cushing's disease'. Together they form a unique fingerprint.

Cite this